Trials / Terminated
TerminatedNCT00061646
Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
A Phase II Single-Arm Study Evaluating the Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-510/Thrombospondin-1 mimetic | |
| DRUG | Carboplatin/Taxol |
Timeline
- Start date
- 2003-03-01
- First posted
- 2003-06-04
- Last updated
- 2007-08-14
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00061646. Inclusion in this directory is not an endorsement.